🔗 Share this article

While America continues making sweeping revisions to its vaccination guidelines, one figure appears somewhat surprisingly: Høeg, a Danish American physician and epidemiologist who first made her name by questioning Covid vaccines during the global health crisis and has zeroed in on possible deaths following Covid immunization in her short position at the US Food and Drug Administration (FDA).

Proposed Overhauls to Childhood Vaccine Schedule

Agency leaders had intended to reveal sweeping changes to the childhood vaccine schedule earlier this month, bringing the US with the Danish national calendar, sources say – a substantial departure that would place the US at odds with many the global community with little proof for improved outcomes. The announcement has been pushed back until the new year.

Instead of Vinay Prasad, Dr. Høeg is set to present at the gathering. She was recently named interim head of the FDA’s CDER, the fifth appointee to head the office this year.

A Shift at the Agency

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it points to a increased emphasis upon dismantling long-standing vaccines at the FDA.

Høeg has often pushed for ending certain pediatric immunization guidelines in the US to become more like Denmark's approach, a country with universal health coverage and a number of inhabitants about the population of Wisconsin’s.

To date public appearances, she has continued to focus on vaccines – traditionally the domain of Dr. Prasad, director of the FDA’s CBER – instead of medication approval.

Doubts Over Qualifications

Dr. Høeg has little discernible background in drug development, regulation or management, which has been standard for past directors of the biologics center. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since spring.

“She appears not to have the necessary background” for leading the drug-regulation department, stated a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She lacks experience in leading a major agency. She is not an expert in drug approvals.”

Past directors of CBER would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, said a former acting FDA commissioner. “Clearly, she has not acquired the kind of background that prior appointees who ran the center have had.”

CDER has an vast portfolio at the FDA, she emphasized.

“The public just zeroes in on the innovative therapies, but the generic drug division authorizes numerous generic drugs. There’s a biologic copycat branch, over-the-counter program and other areas, and every single one must be looked after,” Woodcock said. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

There is also, a significant management aspect to the job, which supervises in excess of 5,000 personnel. “It’s a enormous leadership role, if you perform it correctly,” Woodcock said.

Response and Contentious Initiatives

In response to questions about Dr. Høeg's fitness for the role and whether this selection signifies greater collaboration among regulatory chiefs on vaccines, a representative said that the “questions are based on inaccurate assumptions”.

“Her experience is consistent with the functions of her job,” the official explained, citing the time Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including computational safety modeling and shot safety tracking”.

As acting director, Høeg inherits the commissioner’s controversial priority voucher program, a disputed rapid drug-approval program that allegedly troubled her predecessors. “How are these medications being chosen for this voucher program? Who makes the choices?” Howard questioned. “There is a lot of lack of transparency going on at the regulatory body right now.”

Overall, he said, “the FDA appears to be shifting towards less stringent oversight of all drugs, aside from vaccines.”

Established Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a clearer, if problematic, history, some experts have noted. She authored a study using unconfirmed crowd-sourced reports to assess the rate of myocarditis after COVID-19 immunization. She consulted for the Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccines are more dangerous than they are.

Among her “wish list” for the new administration featured revising guidelines for new vaccines and ending “non-essential” vaccines, she said following the vote on a audio program. At the agency, Høeg has according to sources floated the idea of barring teenage boys from receiving COVID-19 vaccinations.

“She is an complete ideologue who commences with her conclusions and reverse-engineers to fit the evidence in a highly deceptive, dishonest manner,” Dr. Howard stated.

Taking Control and a “Revenge Tour”

Høeg joined fellow contrarians, {like|